Redesign Science

Redesign Science is a biotechnology company listed in the New York City AI sector [1]. Founded in 2017, the company operates as a platform biotech at the interface of physics-based molecular simulation and deep learning to create generative AI for drug discovery [2]. Redesign Science deploys its platform technology to develop Protein Interaction Modulators targeting validated targets associated with oncogenic and inflammatory diseases [2]. According to LinkedIn, the company operates in the biotechnology research industry [3].

Something wrong or missing? Send a correction. Fixed within 24 hours.